Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference.

Cancer research·2026
Same author

Nucleophagy removes cytotoxic trapped PARP1.

Nature cell biology·2026
Same author

DNA-induced conformational changes in SPRTN relieve its auto-inhibitory effect on protease activity.

bioRxiv : the preprint server for biology·2026
Same author

[Corrigendum] Influence of MLH1 on colon cancer sensitivity to poly(ADP‑ribose) polymerase inhibitor combined with irinotecan.

International journal of oncology·2026
Same author

The vital role of p97/valosin-containing protein-mediated degradation pathways in tumour immunity.

Current opinion in cell biology·2026
Same author

Dynamins maintain nuclear envelope homeostasis and genome stability.

Nature communications·2026

Related Experiment Video

Updated: Mar 27, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.7K

Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.

Jutta Zimmer1, Eliana M C Tacconi1, Cecilia Folio1

  • 1Genome Stability and Tumourigenesis Group, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.

Molecular Cell
|January 11, 2016
PubMed
Summary

G-quadruplex (G4) stabilizers like pyridostatin selectively kill homologous recombination (HR)-defective cancer cells by increasing DNA damage. This offers a new therapeutic strategy for HR-deficient tumors, even those resistant to PARP inhibitors.

More Related Videos

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

6.1K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.8K

Related Experiment Videos

Last Updated: Mar 27, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.7K
Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

6.1K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.8K

Area of Science:

  • Genomics
  • DNA repair
  • Cancer biology

Background:

  • G-quadruplex (G4) sequences, found in telomeres, act as replication barriers.
  • Homologous recombination (HR) repairs DNA double-strand breaks (DSBs) and restarts stalled replication forks.
  • HR is crucial for efficient replication of G-rich telomeric repeats.

Purpose of the Study:

  • To investigate the role of G4 formation in telomere instability and replication stress.
  • To evaluate the therapeutic potential of G4-stabilizing drugs in HR-defective cells.

Main Methods:

  • Assessing replication efficiency in HR-deficient cells.
  • Treating cells with the G4-stabilizing compound pyridostatin (PDS).
  • Analyzing DSB accumulation, cell proliferation, and cell cycle progression.

Main Results:

  • HR deficiency significantly decreases telomeric repeat replication efficiency.
  • PDS treatment increases telomere fragility and DSBs in HR-defective cells.
  • PDS reduces proliferation of HR-defective cells, including those resistant to olaparib.

Conclusions:

  • G4 formation contributes to telomere instability.
  • G4-stabilizing drugs like PDS show therapeutic promise for selectively targeting HR-compromised cancers.
  • This approach may overcome resistance to existing therapies like PARP inhibitors.